HER3
Showing 26 - 50 of >10,000
Metastatic Breast Cancer Trial in Charlottesville (HER2 BATs with Pembrolizumab)
Recruiting
- Metastatic Breast Cancer
- HER2 BATs with Pembrolizumab
-
Charlottesville, VirginiaAshley Donihee
Jan 18, 2023
99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast
Enrolling by invitation
- Breast Cancer Female
- 99mTc-DARPinG3 SPECT/CT
-
Tomsk, Russian FederationRussia Tomsk NRMC
Jan 23, 2023
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +5 more
- Trastuzumab
- +2 more
-
Scottsdale, Arizona
- +2 more
Jan 31, 2023
Molecular Imaging in HER2-positive Breast Cancer During
Enrolling by invitation
- HER2-positive Breast Cancer
- Female
-
Tomsk, Russian Federation
- +1 more
Jun 7, 2022
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Breast Cancer Female, Leptomeningeal Metastases Trial in Charlottesville (HER2 BATs)
Terminated
- Breast Cancer Female
- Leptomeningeal Metastases
- HER2 BATs
-
Charlottesville, VirginiaUniversity of Virginia
Dec 15, 2022
Breast Cancer Trial in Detroit (biological, drug, other)
Terminated
- Breast Cancer
- HER2Bi-armed activated T cells
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Nov 29, 2022
HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)
Active, not recruiting
- HER2 Positive Metastatic Breast Cancer
- pyrotinib
- +2 more
-
Beijing, China307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022
HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)
Recruiting
- HER2-positive Metastatic Breast Cancer
- Alpelisib
- +2 more
-
Aurora, Colorado
- +2 more
Dec 29, 2022
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)
Not yet recruiting
- Urothelial Carcinoma
- disitamab vedotin
- +4 more
- (no location specified)
Jun 9, 2023
Breast Cancer Female Trial in Tomsk (99mTc-ADAPT6, 99mTc-DARPinG3)
Recruiting
- Breast Cancer Female
-
Tomsk, Russian FederationTomsk NRMC
May 12, 2022
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +4 more
- Necitumumab
- +4 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial
Recruiting
- Metastatic Salivary Gland Carcinoma
- +4 more
- Docetaxel
- +3 more
-
New York, New YorkMemorial Sloane Kettering Cancer Center
Jan 11, 2023
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copanlisib
- +2 more
-
Los Angeles, California
- +4 more
Jul 19, 2022
Advanced or Metastatic Breast Cancer Trial (PF-07220060, Fulvestrant, Everolimus)
Not yet recruiting
- Advanced or Metastatic Breast Cancer
- PF-07220060
- +3 more
- (no location specified)
Oct 24, 2023
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,
Recruiting
- HER2-positive Breast Cancer
- +4 more
-
Essen, Germany
- +5 more
Nov 15, 2022
Breast Tumors, Breast Cancer, Adenocarcinomas Trial run by the NCI (AdHER2/neu DC Vaccine)
Completed
- Breast Neoplasms
- +3 more
- Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 12, 2022